(8th January 2015) MerLion’s finafloxacin shows positive phase 2 results in complicated urinary tract infections
Singapore, 8 January 2015 - MerLion Pharmaceuticals (“MerLion”), a biopharmaceutical company based in Singapore and Berlin, today announced positive results from a phase 2 trial with finafloxacin, conducted in Europe, treating patients hospitalized with complicated urinary tract infections (cUTI), including a high proportion with pyelonephritis.
Instinctif Partners Contact: Dr. Douglas Pretsell
MerLion Contact: David Dally, CEO
About MerLion Pharmaceuticals
MerLion Pharmaceuticals Pte Ltd is a biopharmaceutical company focused on developing its antibacterial candidate, finafloxacin. MerLion is a privately held company supported by a group of leading global investors including Aravis Venture Partners, Bio*One Capital (a subsidiary of EDBI), Heidelberg Capital and Nomura Research & Advisory. MerLion Pharmaceuticals Pte Ltd is headquartered in Singapore with clinical development operations in Berlin, Germany. For more information please visit www.merlionpharma.com